JNCE
Jounce Therapeutics, Inc.
About JNCE
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. The Company has developed a suite of integrated technologies that consist of its Translational Science Platform, enabling it to interrogate the cellular and molecular composition of tumors. Its program, JTX-8064, is a humanized IgG4, anti-LILRB2 monoclonal antibody designed to reprogram macrophages. JTX-8064 is being developed for patients with either PD-(L)1-inhibitor resistant or PD-(L)1 inhibitor-sensitive tumors. Vopratelimab is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS). Pimivalimab is a clinical-stage anti-PD-1 monoclonal antibody that is being developed primarily for its use in combination with its product candidates.
Buy US stocks in Australia starting with JNCE. Open an account and start investing today!
$63.58M
-
0.00%
0
$1.28
$1.18
$0.00
$8.80
$0.58
JNCE FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in JNCE
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.